Analysts Set Expectations for Exact Sciences Co.’s FY2022 Earnings (NASDAQ:EXAS)

Exact Sciences Co. (NASDAQ:EXASGet Rating) – Investment analysts at William Blair issued their FY2022 EPS estimates for Exact Sciences in a research note issued on Monday, January 9th. William Blair analyst A. Brackmann forecasts that the medical research company will earn ($3.07) per share for the year. The consensus estimate for Exact Sciences’ current full-year earnings is ($3.84) per share. William Blair also issued estimates for Exact Sciences’ Q4 2022 earnings at ($0.82) EPS, Q1 2023 earnings at ($0.71) EPS, Q2 2023 earnings at ($0.50) EPS, Q3 2023 earnings at ($0.28) EPS, Q4 2023 earnings at ($0.32) EPS and FY2023 earnings at ($1.82) EPS.

A number of other analysts have also weighed in on the stock. StockNews.com started coverage on shares of Exact Sciences in a report on Wednesday, October 12th. They issued a “hold” rating for the company. Raymond James reduced their price objective on shares of Exact Sciences from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Monday, November 7th. Piper Sandler raised their price objective on shares of Exact Sciences from $40.00 to $50.00 and gave the company a “neutral” rating in a research note on Monday, November 14th. Craig Hallum raised their price objective on shares of Exact Sciences from $35.00 to $44.00 in a research note on Monday. Finally, SVB Leerink raised their price objective on shares of Exact Sciences from $70.00 to $75.00 and gave the company an “outperform” rating in a research note on Thursday. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $61.57.

Exact Sciences Stock Performance

NASDAQ EXAS opened at $68.54 on Thursday. The firm has a market cap of $12.18 billion, a price-to-earnings ratio of -16.72 and a beta of 1.30. The company has a 50 day moving average of $47.23 and a 200-day moving average of $41.98. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.72. Exact Sciences has a 1-year low of $29.27 and a 1-year high of $84.46.

Exact Sciences (NASDAQ:EXASGet Rating) last posted its quarterly earnings results on Thursday, November 3rd. The medical research company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.26. The firm had revenue of $523.07 million during the quarter, compared to analyst estimates of $500.78 million. Exact Sciences had a negative net margin of 35.73% and a negative return on equity of 22.10%.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Steward Partners Investment Advisory LLC increased its stake in shares of Exact Sciences by 44.4% in the second quarter. Steward Partners Investment Advisory LLC now owns 667 shares of the medical research company’s stock worth $26,000 after buying an additional 205 shares during the period. Ellevest Inc. boosted its stake in Exact Sciences by 103.6% in the 2nd quarter. Ellevest Inc. now owns 682 shares of the medical research company’s stock worth $27,000 after purchasing an additional 347 shares in the last quarter. Signaturefd LLC boosted its stake in Exact Sciences by 45.7% in the 3rd quarter. Signaturefd LLC now owns 957 shares of the medical research company’s stock worth $31,000 after purchasing an additional 300 shares in the last quarter. Householder Group Estate & Retirement Specialist LLC bought a new position in Exact Sciences in the 3rd quarter worth about $33,000. Finally, National Bank of Canada FI lifted its stake in Exact Sciences by 72.6% during the 3rd quarter. National Bank of Canada FI now owns 1,189 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 500 shares during the period. 90.30% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Exact Sciences

In other news, EVP Sarah Condella sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, January 9th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the transaction, the executive vice president now directly owns 85,090 shares in the company, valued at $5,105,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Exact Sciences Company Profile

(Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.

See Also

Earnings History and Estimates for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.